Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Placebo-Controlled, Multicenter Study of Sertraline Treatment for Obsessive-Compulsive Disorder

Kronig, Michael H. MD; Apter, Jeffrey MD; Asnis, Gregory MD; Bystritsky, Alexander MD; Curtis, George MD; Ferguson, James MD; Landbloom, Ronald MD; Munjack, Dennis MD; Riesenberg, Robert MD; Robinson, Delbert MD; Roy-Byrne, Peter MD; Phillips, Kem PhD; Du Pont, Iwona Jeske PhD

Journal of Clinical Psychopharmacology: April 1999 - Volume 19 - Issue 2 - p 172-176
Brief Reports

The safety and efficacy of sertraline versus placebo were examined in a group of nondepressed outpatients with obsessive-compulsive disorder (OCD). Patients with moderate-to-severe OCD were recruited at 10 sites. After a 1-week placebo lead-in, patients were treated in a double-blind fashion for 12 weeks with sertraline or placebo. Sertraline was administered at a starting dose of 50 mg/day, with flexible titration up to 200 mg/day. The efficacy measures were the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the National Institute of Mental Health Global Obsessive Compulsive Scale (NIMH), and the Clinical Global Impression Scale (CGI) Severity of Illness and Improvement subscales. One hundred sixty-seven patients were randomly assigned and received at least one dose of double-blind medication: 86 received sertraline and 81 received placebo. All efficacy measures showed significantly greater improvement in the sertraline group from the end of week 8 until the end of week 12. Significantly greater improvement (p < 0.05) in the sertraline group first became apparent by the end of week 3 on the Y-BOCS and the CGI Improvement scale, and by the end of weeks 6 and 8, respectively, on the NIMH and CGI Severity scale. Sertraline was well tolerated, without serious adverse effects. In conclusion, sertraline was safe and effective in the treatment of patients with OCD. (J Clin Psychopharmacol 1999;19:172-176)

(Kronig, Robinson) Department of Psychiatry, Hillside Hospital of LIJMC, Glen Oaks, New York; (Apter) Princeton Biomedical Research, Princeton, New Jersey; (Asnis) Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York; (Bystritsky) Adult Psychiatry, UCLA, Los Angeles, California; (Curtis) Department of Psychiatry, University of Michigan, Ann Arbor, Michigan; (Ferguson) Pharmacology Research Corporation, Murray, Utah; (Landbloom) Department of Psychiatry, St. Paul-Ramsey Medical Center, St. Paul, Minnesota; (Munjack) Southwest Research Institute, Beverly Hills, California; (Riesenberg) Biobehavioral Research Center, Decatur, Georgia; (Kronig, Robinson) Albert Einstein College of Medicine, Bronx, New York; (Roy-Byrne) Harborview Medical Center, Seattle, Washington; (Phillips, Du Pont) Pfizer, Inc., New York, New York

Received February 5, 1997; accepted after revision April 21, 1998.

Address requests for reprints to: Iwona Jeske Du Pont, PhD, Pfizer, Inc., 235 East 42nd Street, New York, NY 10017.

© 1999 Lippincott Williams & Wilkins, Inc.